Press release
Immune Complex Membranoproliferative Glomerulonephritis Therapeutics Market Size in the 7MM is projected to increase at a significant CAGR by 2034, estimates DelveInsight
Discover the Immune Complex Membranoproliferative Glomerulonephritis New Treatment @ https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Immune Complex Membranoproliferative Glomerulonephritis Market Report
* On February 02, 2026- Novartis Pharmaceuticals initiated a Phase III study is to evaluate the efficacy and safety of iptacopan compared to placebo (both administered in combination with standard of care) in participants (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN. The study aims to demonstrate a reduction in proteinuria and improvement in estimated glomerular filtration rate (eGFR) in participants treated with iptacopan compared to placebo.
* In January 2026, Apellis Pharmaceuticals Inc . announced a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.
* The total diagnosed prevalent population of IC-MPGN in the 7MM was found to be approximately 7,000 in 2023.
* The diagnosed prevalent population of IC-MPGN, in the United States, was found to be approximately 3,770 in 2023.
* In EU4 and the UK, the diagnosed prevalent population of IC-MPGN was found to be the maximum in Germany, followed by Spain in 2023. While the lowest number of cases were found in Italy.
* In Japan, adults are more prevalent towards IC-MPGN compared to the pediatric group.
* The Immune Complex Membranoproliferative Glomerulonephritis Companies such as Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
* Promising Immune Complex Membranoproliferative Glomerulonephritis Therapies such as LNP023, Pegcetacoplan, Danicopan, SGB-9768, Iptacopan and others.
To know more about Immune Complex Membranoproliferative Glomerulonephritis treatment options, visit @ Approved Immune Complex Membranoproliferative Glomerulonephritis Drugs [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Complex Membranoproliferative Glomerulonephritis Overview
Membranoproliferative glomerulonephritis (MPGN) is a kidney disorder involving inflammation and kidney cell changes. It is a form of glomerulonephritis caused by an abnormal immune response. MPGN has previously been used as an umbrella term to describe a spectrum of hypocomplementemic glomerular diseases, which are a rare cause of end-stage kidney disease (ESKD). More recently, MPGN has been reclassified into two diseases: immune-complex MPGN (IC-MPGN) and C3 glomerulopathy (C3G) based on immunofluorescence findings in kidney biopsies: predominant or exclusive C3 deposits in C3G and combined immunoglobulins and complement deposits in IC-MPGN.
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation in the 7MM
* Total Immune Complex Membranoproliferative Glomerulonephritis Incident Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Gender-specific Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Region-specific Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Treated Cases
Discover more about therapy for Immune Complex Membranoproliferative Glomerulonephritis @ Immune Complex Membranoproliferative Glomerulonephritis Clinical Trials [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Complex Membranoproliferative Glomerulonephritis Emerging Drugs
* Iptacopan (LNP023): Novartis Pharmaceuticals
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of CDRDs8-10. It is the most advanced asset in the Novartis nephrology pipeline and has the potential to become the first targeted therapy to delay progression to dialysis in C3G9. Discovered at the Novartis Institutes for BioMedical Research, iptacopan is currently in development for several CDRDs where significant unmet needs exist, including IC-MPGN. Currently, the drug is being investigated in Phase III of the clinical development. Novartis intends to seek regulatory approval for the drug by 2026, with the preliminary findings from the Phase III APPARENT trials expected to be available by the same year.
* Pegcetacoplan (APL-2): Apellis Pharmaceuticals
Apellis' Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. It is a15-amino acid cyclic peptide conjugated to each end of a linear polyethylene glycol molecule that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway. Pegcetacoplan (marketed as EMPAVELI) is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Market Outlook
Immune Complex Membranoproliferative Glomerulonephritis Market Outlook
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is an ultrarare, chronic, and progressive nephropathy, which is characterized by significant immunoglobulin deposition and is assumed to involve dysregulation of both the classical and alternative pathways of complement (AP). IC-MPGN lacks approved medications, creating a significant demand for treatments addressing the root cause. Kidney failure, necessitating dialysis or transplantation, can occur within 5-10 years of diagnosis. Current strategies involve supportive measures with or without traditional immunosuppression, showing limited effectiveness in slowing disease progression. Considering the diseases' pathophysiology, a logical approach involves targeted complement inhibition. The utilization of off-label prescription medications predominantly characterizes the market. IC-MPGN treatments encompass immunosuppressants, steroids, inhibitors of renin-angiotensin-aldosterone system (RAAS), and other supportive therapies like calcineurin inhibitors, additional immunosuppressive agents, and antibodies. The current evolving landscape of IC-MPGN treatment exhibits a mid-level pipeline. Two promising therapies, Iptacopan (Novartis Pharmaceutical) and Pegcetacoplan (Apellis Pharmaceuticals), are in the advanced Phase III developmental stage.
Download the report to understand which factors are driving Immune Complex Membranoproliferative Glomerulonephritis therapeutics market trends @ Immune Complex Membranoproliferative Glomerulonephritis Market Trends [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Complex Membranoproliferative Glomerulonephritis Companies
Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Immune Complex Membranoproliferative Glomerulonephritis Companies- Novartis Pharmaceuticals, Apellis Pharmaceuticals , and others.
* Immune Complex Membranoproliferative Glomerulonephritis Therapies- LNP023, Pegcetacoplan, Danicopan, SGB-9768, Iptacopan and others.
* Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis current marketed and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies
* Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL's views, Analyst's views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement
To learn more about Immune Complex Membranoproliferative Glomerulonephritis Companies working in the treatment market, visit @ Immune Complex Membranoproliferative Glomerulonephritis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of IC-MPGN
4. IC-MPGN Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. IC-MPGN Treatment
9. Clinical Practice Guideline for the Management of Glomerular Diseases: KDIGO 2021
10. IC-MPGN Epidemiology and Patient Population
11. IC-MPGN Patient Journey
12. IC-MPGN Emerging Therapies
13. IC-MPGN: Seven Major Market Analysis
14. IC-MPGN Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-complex-membranoproliferative-glomerulonephritis-therapeutics-market-size-in-the-7mm-is-projected-to-increase-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Complex Membranoproliferative Glomerulonephritis Therapeutics Market Size in the 7MM is projected to increase at a significant CAGR by 2034, estimates DelveInsight here
News-ID: 4388940 • Views: …
More Releases from ABNewswire
CompareForexBrokers achieves B Corporation certification
CompareForexBrokers has been certified as a B Corporation after meeting verified standards of social and environmental performance, transparency and accountability.
MELBOURNE, Australia - February 12, 2026 - CompareForexBrokers [https://www.compareforexbrokers.com/] today confirmed it has been certified as a B Corporation [https://www.bcorporation.net/en-us/find-a-b-corp/company/compare-forex-brokers/] Trademark , following a comprehensive review of its governance, operations and impact across key stakeholder areas.
B Corporation certification is awarded to companies that meet verified standards of social and environmental performance,…
TopMarket.co.il Expands Its Online Electronics Catalog and Customer Services for …
TopMarket.co.il, an established Israeli online electronics retailer founded in 2002, continues expanding its technology catalog while enhancing customer services, nationwide delivery, warranty support, and wholesale options for consumers and businesses.
TopMarket.co.il, a long-established online electronics retailer based in Netanya, continues to expand its multi-category product catalog while strengthening customer service offerings for consumers and businesses across Israel.
Founded in May 2002, TopMarket.co.il began as a small neighborhood computer store [https://www.topmarket.co.il/en/] and repair…
Banu Launches Nationwide Property and Business Owner Data Platform with Built-in …
Banu introduces a free platform offering verified nationwide property and business owner data, integrated CRM, and email, SMS, and phone outreach tools tailored for real estate agents, insurance agents, financial advisors, mortgage & title companies, and other B2B professionals. Sign up without a credit card to access comprehensive data and outreach capabilities.
Outbound marketing for real estate professionals and B2B service providers has become fragmented across multiple tools and unreliable data…
Japan Commercial Construction Market to Reach USD 125.76 Billion by 2031 Driven …
Mordor Intelligence has published a new report on the Japan commercial construction market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Japan Commercial Construction Market Overview
According to Mordor Intelligence, the Japan commercial construction market size [https://www.mordorintelligence.com/industry-reports/japan-commercial-construction-market?utm_source=abnewswire] was valued at USD 107.06 billion in 2025 and is estimated at USD 109.97 billion in 2026, with projections indicating it will reach USD 125.76 billion by 2031, growing at a CAGR…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…
